{"filing":{"accession_number":"0001193125-26-255467","cik":"0001501989","ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"d66030d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526255467/d66030d8k.htm"},"events":[{"id":7171,"run_id":6290,"accession_number":"0001193125-26-255467","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"CytomX entered into Amendment No. 4 to its existing Collaboration and License Agreement with Regeneron on May 29, 2026, which materially expands the scope of the collaboration by extending the program selection period and adding up to eight additional collaboration programs with total potential payments and milestones of approximately $4 billion. The amendment includes immediate nomination payments of $37.0 million for the first two programs, representing a material modification to an existing material agreement that would affect investor assessment of the company's revenue prospects and partnership value.","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3981,"accession_number":"0001193125-26-255467","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"CytomX entered into Amendment No. 4 to its existing Collaboration and License Agreement with Regeneron on May 29, 2026, which materially expands the scope of the collaboration by extending the program selection period and adding up to eight additional collaboration programs with total potential payments and milestones of approximately $4 billion. The amendment includes immediate nomination payments of $37.0 million for the first two programs, representing a material modification to an existing material agreement that would affect investor assessment of the company's revenue prospects and partnership value.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:39.269158+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3981,"accession_number":"0001193125-26-255467","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"CytomX entered into Amendment No. 4 to its existing Collaboration and License Agreement with Regeneron on May 29, 2026, which materially expands the scope of the collaboration by extending the program selection period and adding up to eight additional collaboration programs with total potential payments and milestones of approximately $4 billion. The amendment includes immediate nomination payments of $37.0 million for the first two programs, representing a material modification to an existing material agreement that would affect investor assessment of the company's revenue prospects and partnership value.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:39.269158+00:00","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-03"}]}